Of note, in the previously reported NAVIGATOR trial, avapritinib was found to have a 17% ORR and response duration of 10.2 months among advanced GIST patients with KIT or non-D842V PGDFRA mutation who received at least three prior lines of therapy, suggesting that avapritinib could be of benefit for some patients who have been previously heavily treated [61]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.